To include your compound in the COVID-19 Resource Center, submit it here.

Bimagrumab: Phase II/III data

Top-line data from the double-blind, placebo-controlled, international Phase II/III RESILIENT trial in about 240 patients with sIBM

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE